# LCB02A

Source: https://onco.cc/drugs/lcb02a/  
OnCo record `lcb02a` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LCB02A is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at Claudin 18.2.

## Summary

LCB02A is a monoclonal antibody developed by LigaChem Biosciences. Its target is Claudin 18.2. ClinicalTrials.gov describes the intervention as: CLDN18.2-directed human monoclonal antibody (Ab) linked to a topoisomerase I inhibiting payload. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07460375, plans to enrol 191 participants with primary completion expected 2030-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: Monoclonal antibody directed at Claudin 18.2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of LCB02A: https://clinicaltrials.gov/search?intr=LCB02A
- Sponsor page: https://www.ligachembio.com

## Connected records

- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [LigaChem Biosciences](https://onco.cc/companies/ligachem-biosciences/)
- trials: [A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors](https://onco.cc/trials/nct07460375/)

---
JSON: https://onco.cc/api/v1/entities/lcb02a.json